ABIVAX Société Anonyme (ABVX) vs Cellectis S.A. (CLLS)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| ABVX | CLLS | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
| Size band | MID | SMALL |
| Listing | Nasdaq GM | Nasdaq GM |
| Country | France | France |
| Theme | — | cell-therapy |
| Price and returns | ||
| Last close | $86.50 | $0.97 |
| Return · 1 week | −1.13% | +4.37% |
| Return · 1 month | −10.69% | −34.70% |
| Return · 3 months | −30.37% | −65.97% |
| Return · year to date | −35.34% | −79.86% |
| Return · 1 year | −8.79% | −73.37% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −41.88% | −82.27% |
| 52-week high | $148.83 | $5.45 |
| 52-week low | $69.81 | $0.88 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $7.57B | $97.36M |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $88.64M | $39.87K |
| Employees | 98 | 224 |
| Valuation | ||
| Price to earnings · trailing | n/a (negative earnings) | n/a (negative earnings) |
| Price to earnings · forward | n/a (negative forward earnings) | n/a (negative forward earnings) |
| Price to sales | 1647.65× | 1.99× |
| Price to book | 17.15× | 2.23× |
| Enterprise value to EBITDA | n/a (negative EBITDA) | n/a (negative EBITDA) |
| Enterprise value to revenue | 1420.97× | 0.17× |
| Earnings per share · trailing | -6.08 | -0.64 |
| Profitability | ||
| Gross margin | — | 82.27% |
| Operating margin | −8617.93% | −340.69% |
| Profit margin | −8595.07% | −102.34% |
| Return on equity | −252.35% | −94.54% |
| Return on assets | −62.88% | −11.67% |
| Growth | ||
| Revenue growth | −6.80% | −62.10% |
| Balance sheet and payout | ||
| Debt / equity (%) | 0.33 | 195.66 |
| Current ratio | 5.97 | 1.37 |
| Dividend yield | 0.00% | 0.00% |
| Payout ratio | — | 0.00% |
| Trend and volatility | ||
| RSI · 14 | 38.36 | 23.09 |
| ADX · 14 | 32.86 | 58.26 |
| 50-day average | $102.65 | $2.05 |
| 200-day average | $114.72 | $3.13 |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 4.52% | 9.62% |
The full ABVX analysis
Everything this table leaves out for ABIVAX Société Anonyme: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the ABVX argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full ABVX analysisThe full CLLS analysis
Everything this table leaves out for Cellectis S.A.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the CLLS argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full CLLS analysis